We therefore performed a study to observe different lipidlowering strategies in northeast ne china with respect to lowdensity lipoproteincholesterol ldlc reduction and goal attainments. The hps2thrive investigators, led by dr jane armitage oxford university, uk, randomized 25 673 patients with vascular disease to. Fibrates fibric acid derivates are synthetic ligands for ppar. Lipoprotein apheresis is currently the most effective approved treatment available, with minimal effect conferred by conventional lipid lowering agents. The study enrolled 25,673 patients considered to be at high risk for cardiovascular events. Familial hyperlipidaemia british journal of cardiac nursing. Ldlcholesterol goal attainment under persistent lipidlower. Thrive has followed the health of more than 25,000 people in six countries to study the effects of raising good cholesterol on the prevention of heart attacks and strokes. Reducing cardiovascular risk in type 2 diabetes mellitus. Over 25,000 patients with preexisting cardiovascular disease from the uk, scandinavia and china were recruited into hps2thrive. Effects of extendedrelease niacin with laropiprant in. The study also found that using er niacinlaropiprant did cause sideeffects.
Hps2thrive showed that er niacinlaropiprant does not reduce the risk of heart attacks and strokes and furthermore it does increase the risk of side effects. Morbidity and mortality in patients at high cardiovascular risk remain high, even in those receiving the best current standards of care. Nicotinic acidlaropiprant reduces platelet count but increases mean platelet volume in patients with primary dyslipidemia. What do the results from the hps2thrive study show. While little data are available right now and the press release contains scant information, boden noted that hps2thrive was an allcomers secondary. Triglyceridelowering therapies reduce cardiovascular disease. The heart protection study 2treatment of hdl to reduce the incidence of vascular events hps2thrive showed that adding extendedrelease niacinlaropiprant ernlrpt to statin provided no incremental cardiovascular benefit vs placebo pbo. Prior to randomization, 42 424 patients with occlusive arterial disease were given simvastatin 40 mg plus, if required, ezetimibe 10 mg daily to standardize their lowdensity lipoprotein. Treatment of hdl to reduce the incidence of vascular events.
Pdf nicotinic acidlaropiprant reduces platelet count but. Hdl promotes cellular cholesterol efflux and reverse cholesterol transport from lipidladen macrophages figure 1, and prevents lipoprotein oxidation. The primary aim of hps2thrive is to assess the effect of er niacin. Atherosclerosis is a chronic, inflammatory disease of the arterial wall that underlies many of the common causes of cardiovascular morbidity and mortality, including myocardial infarction mi, and cerebrovascular and peripheral vascular disease. Merck announced today that the hps2 thrive heart protection study 2.
There has been renewed interest in nicotinic acid owing to the need for improved prevention of atherosclerosis in patients already taking. In the past, considerable emphasis was placed on reduction of plasma glucose as the key to lowering cardiovascular risk and there were misplaced perceptions of benefit from aspirin in all patients. Plant sterol enriched functional food and atherosclerosis. The heart protection study 2treatment of hdl to reduce the incidence of vascular events hps2. Hps2thrive involved over 25,000 volunteers aged between 50 and 80 with a history of heart disease, stroke or other circulatory disease recruited from almost 250 hospitals in 6 countries china, denmark, finland, norway, sweden and the united kingdom. The selection of antihypertensive drug therapy in patients with diabetes mellitus. The study subjects were all on simvastatin 40 mgday. Laropiprant was a drug used in combination with niacin to reduce blood cholesterol ldl and vldl that is no longer sold, due to increases in sideeffects with no cardiovascular benefit. This article will discuss the studies supporting this optimal systolic blood pressure goal. Are the results from hps2 thrive consistent with previous studies. The heart protection study 2treatment of hdl to reduce the incidence of vascular events hps2thrive study was a randomized, multicenter, doubleblind, prospective, controlled clinical trial that recruited patients at 245 sites in the united kingdom, scandinavia, and china and was published in the new england journal of medicine in july 2014. A low level of highdensity lipoprotein cholesterol hdlc is an established predictor of the risk of coronary heart disease chd. Mar 09, 20 the results of hps2 thrive were disappointing but clear, said jane armitage, who presented the results this morning at the acc in san francisco.
What do the results from the hps2 thrive study show. While we do not yet have a description of the hsp file format and what it is normally used for, we do know which programs are known to open these files. Statin therapy has been well established as a cornerstone of cardiovascular prevention, and yet despite potent therapies for lowering low. This retrospective study analyzed the incidence of cardiovascular events cve and pancreatitis as well as the therapeutic regimen in patients being treated for hypertriglyceridemia htg at an outpatient department. Are the results from hps2thrive consistent with previous studies. A randomized trial of the longterm clinical effects of raising hdl cholesterol with extended release niacinlaropiprant does extended release er niacinlaropiprant prevent vascular events in highrisk. The primary endpoint was the time to first major vascular event mve, defined as the composite of nonfatal mi or coronary death, any stroke, or any arterial. Hps2thrive is a large randomized trial assessing the effects of extended release er niacin in patients at high risk of vascular events. Niacin and progression of ckd american journal of kidney. Hps2thrive treatment of hdl to reduce the incidence of. Hps2thrive showed that adding niacinlaropiprant to effective statinbased ldl cholesterollowering therapy in patients known to have vascular disease did not significantly reduce the risk of. C were similar to those achieved in plant sterol studies hps2.
Nutrition and nutritional supplements in the management of. However, the understanding from genetic studies and negative results from randomised trials that low hdl cholesterol might not cause cardiovascular disease as originally thought has now generated renewed. Easily share your publications and get them in front of issuus. Three cetp inhibitors have failed in phase 3 trials, bringing into question hdlc as a therapeutic target. The following pdf documents describe the data analysis plan for the thrive study. Dec 20, 2012 the largestever study of niacin has failed to show a clinical benefit for niacin and even found a strong signal of harm. Laropiprant itself has no cholesterol lowering effect, but it reduces facial flushes induced by niacin. The good news means this study your study is ontrack to report its. While we do not yet have a description of the hps file format and what it is normally used for, we do know which programs are known to open these files. Current guidelines support lowering of the systolic blood pressure in diabetic patients with hypertension to less than 140 mmhg. Nicotinic acid plus laropiprant suspended for dyslipidaemia. It is well established that lipoproteina lpa is an independent cardiovascular risk factor and predictor of major adverse cardiovascular events. Hps2thrive randomized placebocontrolled trial in 25673.
Issuu is a digital publishing platform that makes it simple to publish magazines, catalogs, newspapers, books, and more online. If you use mozilla firefox, and see the warning this pdf document might not be displayed correctly choose to open with different viewer. Are there any patients who should take er niacinlaropiprant. Merck announced today that the hps2 thrive h eart p rotection s tudy 2 t reatment of h dl to r educe the i ncidence of v ascular e vents study did not meet its primary endpoint. A crosssectional study dysischina was conducted in 2012, involving 25,317 patients from 122 centers across china who were diagnosed with hyperlipidemia and treated with lipidlowering. Of those enrolled, 14,741 were from europe the united kingdom and scandinavia and 10,932 were from china. Genomewide association study identifies a novel genetic risk factor for recurrent venous thrombosis hugoline g. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling. Hps2thrive randomized placebocontrolled trial in 25673 high.
Is a biocompatible and eto, steam, ebeam and gamma sterilizable grade containing higher amount of mold release than hps2. The impact of lipoprotein apheresis in patients with. It has been studied extensively and tested in clinical trials of atherosclerotic cardiovascular disease prevention and regression in the general population, but not specifically in patients with chronic kidney disease ckd, who are at extremely high residual risk despite current therapy. C in patients with very high baseline levels or statin intolerance, or iii. The results of hps2thrive were disappointing but clear, said jane armitage, who presented the results this morning at the acc in san francisco. Apr 18, 2007 treatment of hdl to reduce the incidence of vascular events hps2 thrive hps2 thrive the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. A growing body of evidence suggests that aggressively lowering raised lpa may improve. Thrive trial found higher incidence rates of adverse reactions, including bleeding, in patients receiving the combination of extended. Hps2thrive randomized placebocontrolled trial in 25 673. Safety assessment of niacin in the us food and drug. Many thanks as thrive moves into its final phase final issue spring 2012 hps2thrive is a remarkable study aiming to improve heart health and it is now coming to a close.
Hps2 differs from the other forms of hps in that it includes immunodeficiency, and patients with hps2 have an increased susceptibility to infections due to congenital neutropenia jung et al. Hps2thrive was independently conducted by the clinical trial service unit at oxford university and funded by merck. Listing a study does not mean it has been evaluated by the u. Offers mediumhigh flow, formulation control, good ductility, toughness and clarity. Triglycerides and cardiovascular disease the lancet. The welldocumented antiatherogenic activity is believed to result from its antidyslipidemic effects, which are accompanied by unwanted effects, especially a flush. Combining the outcomes of hps2thrive with the negative outcomes of trials of novel agents that increase hdl cholesterol eg, torcetrapib in illuminate and dalcetrabib in daloutcomes suggest that the previous understanding of hdl as an independent risk factor for chd is incorrect or is an oversimplification of the complex molecules true role. After the introduction of statins, clinical emphasis first focussed on ldl cholesterollowering, then on the potential for raising hdl cholesterol, with less focus on lowering triglycerides. Early pathological descriptions viewed atherosclerosis as an endstage degenerative process that inevitably resulted in a generalized narrowing of. Hps2 thrive treatment of hdl to reduce the incidence of vascular events concluded that adding er niacinlaropiprant to current standard treatment did not produce worthwhile reductions in the risk of heart attacks, strokes and operations to open blocked arteries. Niacin is the oldest drug available for the treatment of dyslipidemia. Hps2thrive, the worlds largest study into the bene.
The hps2 thrive investigators, led by dr jane armitage oxford university, uk, randomized 25 673 patients with vascular disease to 2 g of extendedrelease niacin and 40 mg. Nicotinic acid niacin has been used for decades to prevent and treat atherosclerosis. Every day thousands of users submit information to us about which programs they use to open specific types of files. Treatment of hdl to reduce the incidence of vascular events hps2thrive hps2thrive the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Hps2thrive treatment of hdl to reduce the incidence of vascular events concluded that adding er niacinlaropiprant to current standard treatment did not produce worthwhile reductions in the risk of heart attacks, strokes and operations to open blocked arteries. Merck announced today that the hps2thrive h eart p rotection s tudy 2 t reatment of h dl to r educe the i ncidence of v ascular. Data analysis plan for early safety analyses hps2thrive. Targeting plasma lipids is a mainstay of preventing and treating cardiovascular disease. This article provides an overview of the different types of familial hyperlipidaemia that may be encountered in clinical practice, namely, familial combined hyperlipidaemia fch and familial hypercholesterolaemia fh. Cardiovascular disease risk reduction by raising hdl.
Cardiovascular outcomes trials of fibrates, niacin, or omega3 fatty acids alone, or added to a statin, have not consistently demonstrated reduced risk, but larger, statistically significant clinical benefits have been reported in subgroups with elevated triglycerides tg andor elevated tg plus low highdensity lipoprotein cholesterol hdlc. Thrive due in 20 will hopefully provide answers on the efficacy and safety of niacin plus laropiprant in cardiovascular disease armitage et al. In hps2thrive, the er niacin was combined with a new drug called laropiprant which is a prostaglandin receptor blocker in order to reduce problems due to flushing. The last decade has seen a radical change in our assumptions about the best ways to lower cardiovascular risk in patients with type 2 diabetes mellitus.
Ernlrpt was also associated with an excess of serious adverse experiences aes, some of which were unexpected infections and bleeding. The largestever study of niacin has failed to show a clinical benefit for niacin and even found a strong signal of harm. The european medicines agency ema has recommended suspending marketing authorisations for medicines containing a combination of nicotinic acid and laropiprant for the treatment of adults with dyslipidaemia after a study did not meet its primary endpoint and showed increased risk of serious adverse events. Hermanskypudlak syndrome hps is a rare autosomal recessive disease characterized by platelet defects and oculocutaneous albinism. Owing to their complexity, apolipoprotein disorders will not be covered.
1254 163 1286 32 1561 327 267 1468 80 330 328 204 1517 213 1307 1311 1292 1549 166 1027 1009 607 1197 1205 1224 1664 457 870 122 902 909 1247 383 925 661 1028 1323 498 31 821 800 1155 192 1133 40